未找到相关数据
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC) in the JAVELIN Bladder 100 trial: Subgroup analysis by duration of treatment-free interval (TFI) from end of chemotherapy to start of maintenance.
被引：8
作者：
Sridhar, Srikala S.
Powles, Thomas
Loriot, Yohann
Duran, Miguel A. Climent
Gupta, Shilpa
Tsuchiya, Norihiko
Bamias, Aristotelis
Ardizzoni, Andrea
Ullen, Anders
Huang, Bo
Costa, Nuno Matos
Laliberte, Robert J.
Di Pietro, Alessandra
Sternberg, Cora N.
Grivas, Petros
机构：
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Queen Mary Univ London, Barts Canc Inst, St Bartholomews Hosp, Expt Canc Med Ctr, London, England
[3] Univ Paris Saclay, INSERMU981, Gustave Roussy, Villejuif, France
[4] Inst Valenciano Oncol, Valencia, Spain
[5] Cleveland Clin, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA
[6] Yamagata Univ, Fac Med, Dept Urol, Yamagata, Japan
[7] Natl & Kapodistrian Univ Athens, Alexandra Gen Hosp, Sch Med, Athens, Greece
[8] Azienda Osped Univ Policlin S Orsola Malpighi, Bologna, Italy
[9] Karolinska Univ Hosp, Genitourinary Oncol Unit, Dept Pelv Canc, Solna, Sweden
[10] Pfizer, Groton, CT USA
[11] Pfizer, Porto Salvo, Portugal
[12] Pfizer, Cambridge, MA USA
[13] Pfizer Srl, Milan, Italy
[14] Weill Cornell Med, Englander Inst Precis Med, Hematol Oncol, New York, NY USA
[15] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.4527
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4527
引用
收藏
页数：3
相关论文